Liraglutide/Semaglutide battle: Diabetes Benefits v Weight Loss - WHO WILL WIN?
I've decided that I will reduce the demand from patients with diabetes who might benefit from taking Liraglutide or Semaglutide. The stress and anxiety caused by supply failures is more than the benefit from the drugs.
The global supply issues, with these drugs being bought under the counter for weight loss, are not being managed by manufacturers. A recent search revealed private clinics offering these drugs for over £170 per pen. That is profiteering.
Having considered:
1. The personal benefits to me, measured in less stress and anxiety, is far more valuable than the benefits of using either drug.
2. My opinion of Novo Nordisk is badly tainted, they are on one side of the dividing line between morality and profiteering. Showing a lack of support for patients with diabetes reveals a damning attitude undermining patients with diabetes.
3. I will stop using liraglutide (Victoza), after changing from Semaglutide (Ozempic) due to the same supply issues, to reduce demand. Economics is a powerful tool which will level the playing field.
Sadly, Novo Nordisk will lose the potential of supplying me for a lifetime.